Cargando…
Trends in Kaposi's sarcoma-associated Herpesvirus antibodies prior to the development of HIV-associated Kaposi's sarcoma: A nested case-control study
HIV-associated Kaposi's sarcoma (KS) is a public health challenge in sub-Saharan Africa since both the causative agent, Kaposi's sarcoma associated-herpesvirus (KSHV), and the major risk factor, HIV, are prevalent. In a nested case-control study within a long-standing clinical cohort in ru...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Blackwell Publishing Ltd
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4529666/ https://www.ncbi.nlm.nih.gov/pubmed/25395177 http://dx.doi.org/10.1002/ijc.29329 |
_version_ | 1782384813816152064 |
---|---|
author | Wakeham, Katie Johnston, W Thomas Nalwoga, Angela Webb, Emily L Mayanja, Billy N Miley, Wendell Elliott, Alison M Whitby, Denise Newton, Robert |
author_facet | Wakeham, Katie Johnston, W Thomas Nalwoga, Angela Webb, Emily L Mayanja, Billy N Miley, Wendell Elliott, Alison M Whitby, Denise Newton, Robert |
author_sort | Wakeham, Katie |
collection | PubMed |
description | HIV-associated Kaposi's sarcoma (KS) is a public health challenge in sub-Saharan Africa since both the causative agent, Kaposi's sarcoma associated-herpesvirus (KSHV), and the major risk factor, HIV, are prevalent. In a nested case-control study within a long-standing clinical cohort in rural Uganda, we used stored sera to examine the evolution of antibody titres against the KSHV antigens K8.1 and latency-associated nuclear antigen (LANA) among 30 HIV-infected subjects who subsequently developed HIV-related KS (cases) and among 108 matched HIV/KSHV coinfected controls who did not develop KS. Throughout the 6 years prior to diagnosis, antibody titres to K8.1 and LANA were significantly higher among cases than controls (p < 0.0001), and titres increased prior to diagnosis in the cases. K8.1 titres differed more between KS cases and controls, compared to LANA titres. These differences in titre between cases and controls suggest a role for lytic viral replication in the pathogenesis of HIV-related KS in this setting. |
format | Online Article Text |
id | pubmed-4529666 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2015 |
publisher | Blackwell Publishing Ltd |
record_format | MEDLINE/PubMed |
spelling | pubmed-45296662015-08-13 Trends in Kaposi's sarcoma-associated Herpesvirus antibodies prior to the development of HIV-associated Kaposi's sarcoma: A nested case-control study Wakeham, Katie Johnston, W Thomas Nalwoga, Angela Webb, Emily L Mayanja, Billy N Miley, Wendell Elliott, Alison M Whitby, Denise Newton, Robert Int J Cancer Infectious Causes of Cancer HIV-associated Kaposi's sarcoma (KS) is a public health challenge in sub-Saharan Africa since both the causative agent, Kaposi's sarcoma associated-herpesvirus (KSHV), and the major risk factor, HIV, are prevalent. In a nested case-control study within a long-standing clinical cohort in rural Uganda, we used stored sera to examine the evolution of antibody titres against the KSHV antigens K8.1 and latency-associated nuclear antigen (LANA) among 30 HIV-infected subjects who subsequently developed HIV-related KS (cases) and among 108 matched HIV/KSHV coinfected controls who did not develop KS. Throughout the 6 years prior to diagnosis, antibody titres to K8.1 and LANA were significantly higher among cases than controls (p < 0.0001), and titres increased prior to diagnosis in the cases. K8.1 titres differed more between KS cases and controls, compared to LANA titres. These differences in titre between cases and controls suggest a role for lytic viral replication in the pathogenesis of HIV-related KS in this setting. Blackwell Publishing Ltd 2015-06-15 2014-11-14 /pmc/articles/PMC4529666/ /pubmed/25395177 http://dx.doi.org/10.1002/ijc.29329 Text en © 2014 The Authors. Published by Wiley Periodicals, Inc. on behalf of UICC. http://creativecommons.org/licenses/by/4.0/ This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Infectious Causes of Cancer Wakeham, Katie Johnston, W Thomas Nalwoga, Angela Webb, Emily L Mayanja, Billy N Miley, Wendell Elliott, Alison M Whitby, Denise Newton, Robert Trends in Kaposi's sarcoma-associated Herpesvirus antibodies prior to the development of HIV-associated Kaposi's sarcoma: A nested case-control study |
title | Trends in Kaposi's sarcoma-associated Herpesvirus antibodies prior to the development of HIV-associated Kaposi's sarcoma: A nested case-control study |
title_full | Trends in Kaposi's sarcoma-associated Herpesvirus antibodies prior to the development of HIV-associated Kaposi's sarcoma: A nested case-control study |
title_fullStr | Trends in Kaposi's sarcoma-associated Herpesvirus antibodies prior to the development of HIV-associated Kaposi's sarcoma: A nested case-control study |
title_full_unstemmed | Trends in Kaposi's sarcoma-associated Herpesvirus antibodies prior to the development of HIV-associated Kaposi's sarcoma: A nested case-control study |
title_short | Trends in Kaposi's sarcoma-associated Herpesvirus antibodies prior to the development of HIV-associated Kaposi's sarcoma: A nested case-control study |
title_sort | trends in kaposi's sarcoma-associated herpesvirus antibodies prior to the development of hiv-associated kaposi's sarcoma: a nested case-control study |
topic | Infectious Causes of Cancer |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4529666/ https://www.ncbi.nlm.nih.gov/pubmed/25395177 http://dx.doi.org/10.1002/ijc.29329 |
work_keys_str_mv | AT wakehamkatie trendsinkaposissarcomaassociatedherpesvirusantibodiespriortothedevelopmentofhivassociatedkaposissarcomaanestedcasecontrolstudy AT johnstonwthomas trendsinkaposissarcomaassociatedherpesvirusantibodiespriortothedevelopmentofhivassociatedkaposissarcomaanestedcasecontrolstudy AT nalwogaangela trendsinkaposissarcomaassociatedherpesvirusantibodiespriortothedevelopmentofhivassociatedkaposissarcomaanestedcasecontrolstudy AT webbemilyl trendsinkaposissarcomaassociatedherpesvirusantibodiespriortothedevelopmentofhivassociatedkaposissarcomaanestedcasecontrolstudy AT mayanjabillyn trendsinkaposissarcomaassociatedherpesvirusantibodiespriortothedevelopmentofhivassociatedkaposissarcomaanestedcasecontrolstudy AT mileywendell trendsinkaposissarcomaassociatedherpesvirusantibodiespriortothedevelopmentofhivassociatedkaposissarcomaanestedcasecontrolstudy AT elliottalisonm trendsinkaposissarcomaassociatedherpesvirusantibodiespriortothedevelopmentofhivassociatedkaposissarcomaanestedcasecontrolstudy AT whitbydenise trendsinkaposissarcomaassociatedherpesvirusantibodiespriortothedevelopmentofhivassociatedkaposissarcomaanestedcasecontrolstudy AT newtonrobert trendsinkaposissarcomaassociatedherpesvirusantibodiespriortothedevelopmentofhivassociatedkaposissarcomaanestedcasecontrolstudy |